GMED
Globus Medical, Inc.
GMED has the edge over OSCR overall, supported by stronger valuation and lower modeled downside.
OSCR
Oscar Health, Inc.
OSCR's outlook is improving, though it still trails on the overall score.
GMED Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
GMED's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
GMED PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $72.30 | — |
| Current | 18x | $72.30 | — |
| Cheap | 26x | $106 | +46% |
| Fair | 41x | $166 | +129% |
| Expensive | 70x | $283 | +291% |
Historical ranges are pointers, not guarantees.
GMED has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
GMED Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect GMED's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over GMED on the outlook, with more favorable revenue expectations.
GMED Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.18 | +28% |
| Q3 2026 | $4.05 | +31% |
| Q2 2026 | $3.89 | +50% |
| Q1 2026 | $4.28 | +219% |
| Q4 2025 | $3.92 | +423% |
| Q3 2025 | $3.10 | +349% |
| Q2 2025 | $2.60 | +713% |
| Q1 2025 | $1.34 | +103% |
| Q4 2024 | $0.75 | -37% |
GMED has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
GMED Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $763.7M | -0.7% |
| Q2 2026 | $789.6M | +5.9% |
| Q1 2026 | $759.9M | +27% |
| Q4 2025 | $826.4M | +26% |
| Q3 2025 | $769M | +23% |
| Q2 2025 | $745.3M | +18% |
| Q1 2025 | $598.1M | -1.4% |
| Q4 2024 | $657.3M | +6.6% |
GMED's revenue is growing: $764M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +5.4 points |
| Q2 2026 | 23% | +13 points |
| Q1 2026 | 20% | +3.6 points |
| Q4 2025 | 20% | +11 points |
| Q3 2025 | 18% | +10 points |
| Q2 2025 | 10% | +2.3 points |
| Q1 2025 | 16% | +15 points |
| Q4 2024 | 9.2% | +7.5 points |
GMED has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over GMED on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
GMED Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $224.8M | +5.1% |
| Q2 2026 | $176.6M | +464% |
| Q1 2026 | $162.7M | +15% |
| Q4 2025 | $202.4M | +4.7% |
| Q3 2025 | $213.9M | +32% |
| Q2 2025 | $31.3M | +18% |
| Q1 2025 | $141.2M | +493% |
| Q4 2024 | $193.2M | +136% |
GMED has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
GMED Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -1.4M shares |
| 1 year | +0.5% | +623K shares |
| 3 years | +18% | +20.8M shares |
| 5 years | +30% | +31.6M shares |
| Available history | +33% | +34M shares |
GMED has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $142.9M |
| Q2 2026 | $136.1M |
| Q1 2026 | — |
| Q4 2025 | $45M |
| Q3 2025 | $40M |
| Q2 2025 | $25M |
| Q1 2025 | $190.5M |
| Q4 2024 | $1M |
GMED spent $324M buying back its own shares over the past year, up 26% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
GMED Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.6x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
| Q4 2025 | -0.7x | Net Cash |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -1.9x | Net Cash |
GMED has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over GMED on leverage, with a lower net debt burden relative to earnings.
GMED Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.8 | Neutral |
| Stochastic | 15.8 | Oversold |
GMED's weekly RSI is 42 (neutral) and its Stochastic is 16 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
GMED PE vs Healthcare Sector
| Metric | GMED | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 31% below |
| PE % | 0 | 29 | 29 pts below |
GMED is trading at 18x earnings, a 31% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over GMED on valuation relative to its sector.
GMED Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $75.5 | 4.3% below |
| 20 week MA | $78.0 | 7.3% below |
| 50 week MA | $83.6 | 14% below |
| 100 week MA | $76.5 | 5.5% below |
| 200 week MA | $68.5 | 5.6% above |
GMED has fallen below most of its moving averages, though it's still 5.6% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over GMED on trend strength, trading above more of its moving averages.
GMED Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.9 | $65.3 | +11% |
| 2021 | $65.3 | $72.2 | +11% |
| 2022 | $72.2 | $73.9 | +2.3% |
| 2023 | $73.9 | $53.3 | -28% |
| 2024 | $53.3 | $83.6 | +57% |
| 2025 | $83.6 | $88.4 | +5.8% |
| 2026 YTD | $88.4 | $72.3 | -18% |
GMED has finished higher in five of the last six years. It's down 18% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over GMED on returns for 2026, with the stronger performance.